CFO transition
OptimizeRx Corporation CFO transition: Mr. D'Silva to succeed Edward Stelmakh
OptimizeRx Corporation reported in a Form 8-K filed August 12, 2026 that Mr. D'Silva will succeed Edward Stelmakh as Chief Financial Officer, effective January 1, 2027.
In the filing's words
Edward Stelmakh will step down as Chief Financial & Strategy Officer effective December 31, 2026. Mr. Andrew D’Silva will become Chief Financial Officer and Ms. Heather Favazza will become Chief Accounting Officer, each effective January 1, 2027.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | OptimizeRx Corporation (OPRX) |
|---|---|
| Event | Transition |
| Incoming | Mr. D'Silva |
| Outgoing | Edward Stelmakh |
| Title in the filing | Chief Financial Officer |
| Effective | January 1, 2027 |
| 8-K filed | August 12, 2026 |
| Internal promotion | Yes |
| Prior role (per filing) | Chief Business Officer, OptimizeRx Corporation |
| SEC CIK | 0001448431 |
OptimizeRx Corporation reported this change in a Form 8-K, Item 5.02, filed August 12, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Mr. D'Silva? Send a correction with the primary source.